Company Overview and News
A progressing rate environment, and a strengthening economy have been tailwinds for insurers. With the hike approved by the Federal Reserve in June, marking the sixth increase since December 2016, the rate currently stands at 2%. The second quarter thus continues to enjoy the positive impact of a favorable rate environment, driving the insurer’s investment results as well as the performance of life insurers.
HIIQ TMK TMK
Credit rating giant A.M. Best has revised the outlooks for Torchmark Corporation (TMK - Free Report) and its units. The rating agency has affirmed the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” and the Long and Short-Term Issue Credit Ratings (Long-Term IR and Short-Term IR) for Torchmark. Simultaneously, A.M. Best revised the outlook for the abovementioned ratings from stable to negative.
NGHCP TMK NGHCO NGHCN TMK.PRC TMK.PRB FAF NGHC TMK NGHCZ
The Finance sector is set to kick off its earnings season this week with major banks reporting quarterly results. Improving rate environment and tax cuts should continue to drive the sector’s performance. Per the Earnings Outlook, earnings for the sector are expected to increase 18.5% on 3.6% higher revenues. Insurers, an important component of the Finance sector, are shortly going to release their financial numbers.
UNM TMK TRV SLF PGR TMK CNO SLF ALL MFC MFC CB
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
UA TMK TMK.PRC TMK.PRB UAA AAPL ED TMK
Document As Filed with the Securities and Exchange Commission on June 29, 2018
Estimates for Torchmark Corporation (TMK - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 earnings being raised 0.2% to $6.04. This provider of annuities, whole and term life insurance, accidental death insurance, health insurance, Medicare supplements and long-term healthcare policies carries a favorable VGM Score of B.
TMK TMK.PRC TMK.PRB GM.WS.A GM.WS.B GM.WS.C GWGH GM TMK GM.WSB Y
The largest five individual stock positions are Cisco Systems, Berkshire Hathaway, Baidu Inc., Johnson & Johnson, and Alphabet, and they account for ~49% of the portfolio.
NOW PSX AZO RDSB TOT RDSA MRC RHHBF HSB RHHVF NWLI AMZN CSCO EMR CMCSK MMM WPP CTWS TMK HCS BRK.A AVT HEIO JNJ BK GOOGL RYDBF VZ NVS WFCNP AXELF HAL PM TMK WSM MTSI CCV DVN WFC.PRL AXP CCZ WFC.PRJ GOOG BAX SHEN VZA COP USB WFC.PRT CKX KOF WFC.PRR TMK.PRC WFC.PRQ ANAT TMK.PRB WFC.PRP WFC.PRO WFC.PRN JEF WFC.PRY RYDAF HSBC.PRA WFC.PRX BIDU HSBC WFC.PRW DEO WFC.PRV AGCO HBCYF WFC CTWSP FP WFC.WS HCS.PRB CTWSO SAFRY RDS.B UL RDS.A UNP UN CMCSA MA GSK 0005 SAF CCV.CL RHHBY KHC HSEA HSEB DNOW UNF
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.
LBTY PSX TEVA THI UAL WMT QSR.WI SIRI SHLD MLUSG LBTYK LILAB GM.WS.A GM.WS.B GM.WS.C SRG.PRA BAC BKW UPS AAL USGPF MDLZ SYF TMK BRK.A BK JNJ LILAK VZ GM.WSB BATRA LSXMB WFCNP TMK BATRK PG LSXMA WFC.PRL MTB BATRR AXP WFC.PRJ MCO VZA STOR BAC USB WFC.PRT GS CHTR WFC.PRR TMK.PRC WFC.PRQ TMK.PRB WFC.PRP WFC.PRO WFC.PRN AAPL MON KO BATRB GM USG WFC.PRY QSR WFC.PRX DVA DAL WFC.PRW WFC.PRV LUV IBM WFC WFC.WS FWONB COST LBTYB VRSN AXTA MA LBTYA SNY FWONA V SRG KHC FWONK LSXMK LILA
Document UNITED STATES
Primerica, Inc. (PRI - Free Report) reported first-quarter 2018 operating income of $1.47 per share, missing the Zacks Consensus Estimate of $1.49 by nearly 1.3%. However, the bottom line improved 32.4% year over year on lower effective tax rate (from the legislation of the Tax Cuts and Jobs Act of 2017). Also, ongoing share buybacks offered an additional upside to the bottom line.
TMK LNC TMK.PRC TMK.PRB PRI RGA LNC.WS TMK
Sun Life Financial Inc. (SLF - Free Report) reported first-quarter 2018 underlying net income of $609 million (C$770 million), up 14.5% year over year. This improvement was fueled by interest on par seed capital, strong business growth, the lower U.S. income tax rate and favorable investment experience.
TMK SLF LNC.WS TMK SLF LNC TMK.PRC TMK.PRB GM.WS.A GM.WS.B RGA GM.WS.C SLF.PR.G SLFYF GM GM.WSB SLF.PR.B SLF.PR.E SLF.PR.D SLF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to TMK / Torchmark Corp. on message board site Silicon Investor.
|Trimark Oil and Gas(V.Tmk)|
as of ET